2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Ruchi Bhatt, DO, Jersey Shore University Medical Center, Ocean University Medical Center, Hackensack Meridian Health, discusses the investigation of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer.
The phase 3 DESTINY-Breast04 trial (NCT03734029) compared the safety and efficacy of trastuzumab deruxtecan with physician's choice treatment in patients with HER2-low, unresectable or metastatic breast cancer who received 1 to 2 lines of prior chemotherapy in the metastatic setting.
Previously, HER2-targeted therapies were utilized for patients with HER2-positive breast cancer, classified as HER2 3+ with immunohistochemistry (IHC) or HER2 2+ with IHC and fluorescence in situ hybridization (FISH) assays, Bhatt says, adding that all other patients were considered HER2-negative. However, patients with HER2-low breast cancer, defined as HER2 1+ IHC or HER2 2+ IHC that is not FISH amplified, have emerged as another subgroup within the disease instead of being considered HER2-negative, Bhatt explains.
Defining HER2-low disease has allowed investigators to study targeted agents in new subsets of patients, Bhatt concludes.
Related Content: